Kaifang Zou

Prof. Kaifang Zou

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
DGDi Guo
Di Guo
XLXiaojing Liu
Xiaojing Liu
CZCui Zeng
Cui Zeng
LCLing Cheng
Ling Cheng
GSGengqing Song
Gengqing Song
KZKaifang Zou
Kaifang Zou

1 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YFYu Fu
Yu Fu
LWLlingli Wang
Llingli Wang
CXCheng Xie
Cheng Xie
KZKaifang Zou
Kaifang Zou
LTLei Tu
Lei Tu
XHXiaohua Hou
Xiaohua Hou
Faecal calprotectin and faecal occult blood test (FOBT) were widely used in the diagnosis and assessment of intestinal inflammation in inflammatory bowel disease (IBD). Recently we identified an excellent new biomarker B cell-activating factor (BAFF) for IBD. Here in this study we compared the efficacy of faecal BAFF, calprotectin and FOBT to find the “best non-invasive marker”. Results showed that for discriminating IBD from IBS, BAFF ≥227.3 pg/ml yield 84% sensitivity, 100% specificity, 100% positive predictive value (PPV) and 64% negative predictive value (NPV) while calprotectin ≥50 µg/g yield 76% sensitivity, 93% specificity, 97% PPV and 53% NPV. FOBT yield 65% sensitivity, 93% specificity, 97% PPV and 43% NPV. Combining BAFF with calprotectin tests yield 94% sensitivity, 93% specificity, 98% PPV, 81% NPV. Faecal BAFF level showed the stronger correlation with endoscopic inflammatory score as compared to calprotectin not only in UC (correlation coefficient [r] = 0.69, p < 0.0001 vs. r = 0.58, p < 0.0001), but also in CD (r = 0.58, p < 0.0001 vs. r = 0.52, p = 0.0003). Our results indicating that faecal BAFF is a promising non-invasive biomarker in IBD differential diagnosis and monitoring of intestinal inflammation.


10 January 2022 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CZCui Zeng
Cui Zeng
XLXinghuang Liu
Xinghuang Liu
DXDanping Xiong
Danping Xiong
KZKaifang Zou
Kaifang Zou
Tao BaiTao Bai
Tao Bai

14 August 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
DGDi Guo
Di Guo
JYJun Yang
Jun Yang
FLFangmei Ling
Fangmei Ling
LTLei Tu
Lei Tu
JLJunrong Li
Junrong Li
XHXiaohua Hou
Xiaohua Hou
Background. Clinical data suggest that enteral nutrition (EN) effectively decreases disease activity and maintains remission in patients with inflammatory bowel disease (IBD). However, the modulatory effects of EN on the intestinal mucosal immune system remain unclear. Aims. This study first aimed at comparing the therapeutic effects of three EN formulas on ameliorating dextran sulfate sodium- (DSS-) induced chronic colitis; with the most effective formula, we then examined its influence on the mucosal inflammatory response and epithelial barrier function. Methods. The effect of EN formulas on colitis in mice was assessed by body weight, disease activity index scores, colon length, and H&E staining for pathological examination. Colonic and circulating cytokine expression levels and the frequencies of immune cells were also analyzed. Intestinal epithelial barrier function was evaluated by detecting tight junction proteins. Results. We found that among the three EN formulas, an elemental diet (ED) containing enriched amino acids restored the colitis-related reduction in body weight better than the other two EN formulas. ED amino acids suppressed the release of colonic proinflammatory mediators and maintained the expression of tight junction proteins in these mice. ED amino acid treatment mitigated the colitis-induced increase in CD103+CD11b+ dendritic cells and CD4+ and CD8+ T cells and inhibited the predominant Th1/Th17 responses particularly in the colonic mucosal lamina propria of mice with colitis. Conclusions. We showed that ED amino acids can be an effective immunomodulatory agent to reduce colitis-related inflammation by inhibiting proinflammatory mediators and Th1/Th17 cell responses and by repairing the disrupted epithelial barrier.

1 February 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
CZCui Zeng
Cui Zeng
XLXinghuang Liu
Xinghuang Liu
SZSiran Zhu
Siran Zhu
DXDanping Xiong
Danping Xiong
LZLiangru Zhu
Liangru Zhu
Tao BaiTao Bai
Tao Bai